Published November, 2010
By Federico Innocenti
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.

---

Published November, 2010
By Wafik S. El-Deiry
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

An in depth review of our latest understanding of the molecular events that regulate cell death and those molecules that provide targets for developing agonists or antagonists to modulate death signaling for therapeutic purposes.

---

Published November, 2010
By Dennis M. Brown
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

In their outline and discussion of the use of novel formulation technologies-including synthetic polymers and biomaterials for prolonged or sustained drug release to achieve potentially greater therapeutic effect-they profile those technologies that have resulted in a number of approved and late-stage clinical products.

---

Published November, 2010
By Michael T. Lotze and Michael A. Caligiuri
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression. This volume represents an important investigation into the emerging intersection of cancer biology and cancer immunology.

---

Published November, 2010
By Nicholas B. La Thangue and Lasantha R. Bandara
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

---

Published November, 2010
By Randall E. Harris
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

A section on animal models of carcinogenesis presents comprehensive evidence that general NSAIDs inhibit a variety of malignant neoplasms in vivo, and highlights recent findings which show that COX-2 blocking agents produce striking chemopreventive effects against colon cancer and breast cancer as well as other malignancies.

---

Published November, 2010
By David E. Fisher
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Leading-edge and forward-looking, Tumor Suppressor Genes in Human Cancer illuminates what is currently known of tumor suppressor genes and their regulation, work that is already beginning to revolutionize cancer target elucidation, drug discovery, and treatment design.

---

Published November, 2010
By Eric Verdin
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

A panel of leading investigators summarizes and synthesizes the new discoveries in the rapidly evolving field of histone acetylation as a key regulatory mechanism for gene expression.

---

Published November, 2010
By Benjamin Bonavida
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance.

---

Published November, 2010
By Beverly A. Teicher
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered.

---